As Thanksgiving celebrations began, the US Food and Drug Administration gave Y-mAbs Therapeutics Inc. something extra to celebrate by approving Danyelza for neuroblastoma.
The agency gave the green light to Danyelza (naxitamab) late on 25 November for use in combination with granulocyte-macrophage colony-stimulating...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?